RECEIVED **CENTRAL FAX CENTER**

FEB 1 0 2009

FACSIMILE

Intellectual Property Law

90 Park Avenue .

New York NY 10016

Main

212 336 8000

Fax

212 336 8001

Web

www.arelaw.com

February 10, 2009

To:

Melissa E. Kolom

Fax:

571-273-4139

Leydig, Voit & Mayer, Ltd.

Voice:

571-272-4139

From:

Alan D. Miller Esq.

Re:

U.S. Utility Patent Application No. 10/501,628

Title:

MUTATIONS CAUSED BY ACTIVATION-INDUCED

CYTIDINE DEAMINASE

Inventors: Alberto Martin and Matthew D. Scharff

Your Ref.: 703828 Our File: 96700/905

Prepd. by:

Return to:

rf

No. of pages including cover:

2

JAMES B. MUSKAL
DENNIO R. SCHLEMP CP
JOHN W. KOZAK
MAKE PHELPS
H. MICHAEL HARTMANN
BRUCE M. GAGALA
CHARLES H. MOTTER
JOHN KILVE, JR.
KORKTY F. GREEN
JOHN S. DONKUN
JAMES D. ZALEWA
MARK J. LISS
JOHN M. DELES
JOHN M. DELES
JOHN M. DELES
TALL J. KUBCHAU
STEVEN A. WYAND
PANELA J. RUBCHAU
STEVEN P. PETERSEN
JOHN M. AUGUSTY
PAMELA J. RUBCHAU
STEVEN M. AUGUSTY
WESLEY G. MUELLER
JEREMY M. JAY
LYNH A. SULLIAN

JEREMY M. JAY'
LYNN A. SULLVAN
JEFFREY B. BURGAN
ELEY O. THOMPSON
MARK JOY
DAVID M. AIRAN
XAVICE PILLAI
OREGORY C. SAYS

TAMARA A. BULLER M. DANIX, HEFNER SALIH A. HAFAN KENNETH P. SPRING KENNETH P. SPPENGER AND E. NAFFEIGER** GLAUDIA W. SYANGLE

RECEIVED CENTRAL FAX CENTER

FEB 1 0 2009

LAW OFFICES

LEYDIG, VOIT & MAYER, LTD.

TWO PRUDENTIAL PLAZA, SUITE 4900 CHICAGO, ILLINOIS 60601-6731

> (312) 616-5600 FACSIMILE: (312) 616-5700 WWW.LEYDIG.COM

> > February 10, 2009

Via Electronic Mail

Washington Office 700 Thirteenth Street, N.W., Buite 500 Washington, D.C. Ecoob-3000 (202) 737-4770 Facshmilei (202) 737-4776

ROCKFORD OFFICE 6815 WEAVER ROAD, BUITE 300 ROCKFORD, ILLINGIS 61114-8016 (815) 663-7661 FACEMILE (815) W63-7664

SEATTLE OFFICE I 1420 FIFTH AVENUE: SUITE 3570 SEATTLE: WASHINGTON 98101-4011 (205) 428-3100 FACBINILE: (312) 616-5700

C. PREDERICK LEYDIG BORDON R. COOMS GERTON SCOTT SHEPFARD

TECHNICAL ADVISORS

Kristen J. Harféll Mélissa C. Kolom Rachel J. Meldrich Derek W. Darnett Kathelen H. Helmsychomen Francis J. Koszyk JABON A. MILLER REDECCA B. DIBE YUHI OMOE. JONATHAN M. BPENMER ALAN J. MICEMAN TIMOTHY R. CARLISON R. RAYMONO CHEN

остин па террид прадрам му биз опада 44а. В пете жатала ме тереплена⁴⁴ — Вбечеф Айтонин бит техника

Receipt Acknowly In Solio)

Alan D. Miller, Ph.D., Esq. Amster, Rothstein & Ebenstein LLP 90 Park Avenue New York, New York 10016

JOHN C. ROBENOUIST ROSERT V. JAMED B. RODERTSON** PRANCES M. JAGLA*** CHARLES E. COMER JOSEPH C. CONTRERA* PAUL J. PILBIN JOHN L. GASC. ROBERT T. WITTHANN KEVIN C. PARKO CAROLINE L. STEVENS J. KARL GROSS

CANGLINE L. SEVENS
J, KARL GROSS
J, KARL GROSS
JABON T. MURATA
AARON R. PEDELLSON
L. SCOTT SEALL
NANCY J, GETTER
PETER N. TONNER
STEPHANIE M. LAWALYS
THOMAS R. MERRIDE, JR.
MARGOS P. RIVAS
CHRISTINE M. COCHRAN
JOHN F. SNOW
DINITRY KAPMAR
ANGLE J. BACHL
JOHN K. WINN
ATANA DAS

John K. Winn Atanu das Boris Umansky Kevin C. Keknan Michelle L. Calking Alice C. Su '

CHRISTOPHER K. LEACH

PLEASE ACKNOWLEDGE RECEIPT BY RETURN FAX Horigh

Re:

U.S. Patent Application No. 10/501,628

"Mutations Caused by Activation-Induced Cytidine Deaminase"

(Martin et al. - AECOM) ARE Reference: 96700/905 LVM Reference: 703828

Dear Dr. Miller:

Thank you for your email of November 18, 2008, which forwarded an Office Action in the above-referenced patent application. Please prepare a draft reply to the Office Action in accordance with our instructions, which are set forth below. In order to ensure that the proposed amendments are considered by the Examiner, please also file a Request for Continued Examination (RCE).

Please replace claims 1-9, 13, 15, 18-25, 58, 97, 125, and 262-307 with claims 1-9, 13, 15, 18-25, 58, 97, 125, and 262-307 as set forth in the attached "Proposed Claim Amendments" (redlined and clean claim sets). The amended claims point out more particularly and claim more distinctly the present invention as compared to the existing pending claims. In general, the claims have been amended to clarify that the method comprises inducing and identifying a mutation in a DNA sequence encoding a protein, an antibody, an antibody heavy chain, or a monoclonal antibody. Claims 1, 58, 97, and 125 also have been amended to recite that AID deaminates the DNA sequence. This amendment is supported by the specification at, e.g., paragraphs 0101, 0171, 0194, and 0217. Claim 1 also has been amended to delete the phrase "wherein the gene subject to mutation is within about two kilobases of the promoter." The